Mechanism of Action
Sermorelin acts as a GHRH receptor agonist, stimulating pulsatile GH secretion through the hypothalamic-pituitary axis.
GHRH Receptor Agonism
Sermorelin binds GHRH receptors on pituitary somatotrophs, activating adenylyl cyclase via Gs protein coupling. The resulting cAMP elevation drives GH gene transcription and secretion. As a GHRH analog rather than a GHRP, Sermorelin does not significantly raise cortisol, prolactin, or appetite hormones.[1]Physiological Pulsatility Preservation
Sermorelin's short half-life means it amplifies existing GH pulses rather than creating sustained GH elevation. This more closely mirrors physiological GH secretion than long-acting analogs, which is associated with preserved GH receptor sensitivity and avoidance of negative feedback downregulation.[2]Pituitary Gland Stimulation vs. Direct GH Administration
A key conceptual distinction: Sermorelin stimulates the patient's own pituitary to produce GH, rather than replacing it with exogenous GH. This preserves the pituitary's regulatory feedback capacity and avoids complete suppression of endogenous GH production seen with exogenous GH therapy.[1]Research Overview
GH Deficiency in Children
Phase III ClinicalSermorelin (Geref) was FDA approved for GH deficiency in children based on Phase III trials demonstrating catch-up growth and normalized IGF-1 levels. Efficacy was comparable to exogenous GH with a potentially superior safety profile due to preserved pituitary regulation.[1]
Anti-aging and GH Restoration in Adults
Moderate EvidenceSermorelin is widely used in anti-aging medicine to support GH/IGF-1 levels in adults. Studies show improved sleep quality, body composition, and bone density over 6-12 month protocols. The preservation of pulsatility is considered clinically advantageous over exogenous GH replacement.[2]
Sleep Quality Improvement
Moderate EvidenceBedtime Sermorelin amplifies the dominant nocturnal GH pulse associated with slow-wave sleep. Studies show improved sleep architecture, reduced sleep latency, and higher-quality deep sleep with evening Sermorelin administration, a distinct advantage over morning GHRH dosing.[2]
Calculate your Sermorelin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Anti-aging / GH support | 200–500 µg | Once daily (bedtime) | Subcutaneous |
| Stacked with Ipamorelin | 200 µg Sermorelin + 200 µg Ipamorelin | Before bed | Subcutaneous |
| Conservative start | 200 µg | Once daily (bedtime) | Subcutaneous |
Bedtime is optimal for Sermorelin, amplifies the natural nocturnal GH pulse and improves sleep quality. Fasted state (2-3h post-meal) maximizes GH amplitude. The Sermorelin + Ipamorelin combination (GHRH + GHRP) at bedtime is a common anti-aging compounding pharmacy protocol.
Research protocols only. Not medical advice.
Peptide Interactions
Safety Profile
Sermorelin has an excellent safety profile from FDA-approved Phase III trials and widespread compounding pharmacy use.
WADA: Prohibited as a peptide hormone and growth factor.
Formerly FDA approved: Geref approval from 1997-2008 provides clinical safety reference. Withdrawal was commercial, not safety-related.
Well tolerated: Mild injection site reactions are the most common adverse effect. Flushing, dizziness, and headache are rare at standard doses.
Compounding use: Most current Sermorelin use is through compounding pharmacies for anti-aging applications. Quality and sterility standards vary by compounding pharmacy.
References
- [1]Walker RF. "Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?" Clin Interv Aging. 2006;1(4):307-308.
- [2]Vittone J, et al. "Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men." Metabolism. 1997;46(1):89-96.